GlassScriptPhysician profile
Sean Patrick Phibbs
NPI 1144223579
$9,766.02
in general payments reported to CMS, 2019-2025
33 companies · $3,108 in 2025
The $3,108 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $540 · 2021: $646 · 2022: $1,061 · 2023: $1,693 · 2024: $1,921 · 2025: $3,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,720.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,362.82 | 2023-2025 | M22, Optilight |
| Biotissue Holdings INC. | $1,334.65 | 2021-2025 | |
| Johnson & Johnson Vision Care, INC. | $1,263.39 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,139.54 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $853.51 | 2019-2025 | Tryptyr, Rocklatan, Dailies Total1 |
| Coopervision INC. | $520.06 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Oyster Point Pharma, INC. | $465.93 | 2022-2024 | Tyrvaya |
| Lkc Technologies, INC. | $339.60 | 2023-2025 | |
| Dompe US, INC. | $303.63 | 2024-2025 | Oxervate |
| Allergan, INC. | $291.07 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $232.84 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $221.42 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $215.49 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $200.13 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $172.64 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $106.66 | 2024 | |
| Apellis Pharmaceuticals, INC. | $99.18 | 2023 | Syfovre |
| Maculogix, INC. | $95.42 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $82.99 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $77.29 | 2023 | Spectacle Lenses, Contact Lens |
| Horizon Therapeutics Plc | $75.97 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $52.72 | 2021-2022 | |
| Harrow Eye, LLC | $50.73 | 2025 | Vevye |
| Genzyme Corporation | $43.88 | 2022 | |
| Visioneering Technologies, INC. | $34.21 | 2019 | |
| Abbvie INC. | $27.67 | 2022 | |
| Oasis Medical, INC. | $22.84 | 2019 | |
| Menicon America INC | $16.43 | 2020 | |
| Amgen INC. | $15.31 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $13.81 | 2021 | |
| Shire North American Group INC | $12.98 | 2019 | |
| Alcon Research LLC | $11.07 | 2019 | |
| Optos, INC. | $10.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Phibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.